October 2018

Neuropsychiatric symptoms are now recognized as hallmarks of dementia and are important targets for the development of effective treatments.

With more than a dozen available therapies, disease-modification in multiple sclerosis is entering a new era of development.

Several agents are currently in development geared at the relief of off-time for patients with Parkinson.

Cannabinoids are being explored in a variety of conditions, ranging from Alzheimer disease to migraine.

A novel mesenchymal stem cell therapy produced intriguing phase II data and has moved into a randomized, pivotal phase III clinical trial.

Physicians offer perspectives on newly approved products to prevent migraine.